About this trial
The aim of this clinical trial is to contribute valuable insights into the role of Dexmedetomidine as a synergistic agent in prolonging subarachnoid block duration, with the overarching goal of enhancing perioperative care and surgical success rates.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients of either gender aged between 18 and 65 years.
Patients scheduled for surgical procedures of lower limb requiring subarachnoid anesthesia.
American Society of Anesthesiologists (ASA) physical status classification I or II.
Disqualifiers
Patients with contraindications to subarachnoid anesthesia, including severe coagulopathy, infection at the site of injection, or increased intracranial pressure.
Patients with a history of significant cardiac, respiratory, hepatic, or renal disease.
Pregnant or lactating women.
Patients with a history of substance abuse or dependence.
Trial design
Parallel
Treatments tested in this trial
Hyperbaric bupivacaine
DrugGroup A (Unexposed) will received 2 ml of intrathecal bupivacaine
hyperbaric bupivacaine and dexmedetomidine
DrugGroup B (Exposed) will receive a combination of bupivacaine and Dexmedetomidine infusion
Treatment groups
Trial outcomes
Primary outcomes
Evaluate the efficacy of Dexmedetomidine when used adjunctively with hyperbaric bupivacaine in extending the duration of sensory and motor blockade in subarachnoid anesthesia.
Sensory Blockade Duration: This refers to the time interval from the administration of the subarachnoid block until the complete recovery of sensory function in the dermatomes affected by the anesthesia. It will be assessed using standardized sensory tests, such as pinprick or cold sensation, within the affected dermatomes. Motor Blockade Duration:It encompasses the time from the onset of motor blockade to the complete recovery of motor function and will assessed by evaluating muscle strength and movement capability using modified Bromage score as 0=Subject is able to lift the leg straight and move the hip, knee and ankle. 1. Subject is unable to lift the leg straight but is able to lift the leg straight but is able to flex the knee and ankle freely. 2. Subject is unable to flex the knee and hip, but is able to flex the ankle. 3. Subject is unable to flex the ankle, knee, and hip, but is able to move toes. 4. No movement in the lower extremity.
Secondary outcomes
Investigate the safety profile of Dexmedetomidine in combination with hyperbaric bupivacaine, in term of adverse events such as hypotension, bradycardia, and patient satisfaction.
Sedation levels will be assessed using the Ramsay score 1. Awake; agitated or restless or both 2. Awake; cooperative, oriented, and tranquil 3. Awake but responds to commands only 4. Asleep; brisk response to light glabellar tap or loud auditory stimulus 5. Asleep; sluggish response to light glabellar tap or loud auditory stimulus 6. Asleep; no response to glabellar tap or loud auditory stimulus Adverse Event: will be measured in following term Hypotension: defined as a systolic blood pressure less than 90 mm Hg or a mean arterial pressure below 60 mm Hg. Bradycardia:defined as a heart rate of less than 50 beats per minute. Patient Satisfaction:defined in terms of subjective assessment of the patient's physical and emotional well-being during the procedure include observed signs of distress, facial expressions, and verbal feedback. Patients' satisfaction will be assessed using a 10cm Visual Analogue Score. Where 10cm denoted maximal satisfaction and 0cm denoted minimal.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: